WT1C peptide

WT1C peptide

• Handling and Storage of Synthetic Peptides
• Material Safety Data Sheets (MSDS)

Batch to batch variation of the purity

H-ALLPAVPSL-OH

H-Ala-Leu-Leu-Pro-Ala-Val-Pro-Ser-Leu-OH

9

95.02%

C₄₂H₇₃N₉O₁₁

880.08

Synthetic

Powder

WT1C is a HLA-A*02:01-restricted peptide. WT1C (ALLPAVPSL) showed a high binding score for HLA-A*02:01 but elicited low frequencies of T-cells in individuals. WT1C can be processed from WT1 and presented on HLA-A*02, but its cognate TCR are eliminated during the course of negative selection of thymocytes in nonresponding individuals. WT1C may represent a promising target for TCRm-Ab development.

Normally, this peptide will be delivered in lyophilized form and should be stored in a freezer at or below -20 °C. For more details, please refer to the manual: Handling and Storage of Synthetic Peptides

• Kurosawa, N, Midorikawa, A, Ida, K, Fudaba, YW, Isobe, M. Development of a T-cell receptor mimic antibody targeting a novel Wilms tumor 1-derived peptide and analysis of its specificity. Cancer Sci. 2020; 111: 3516- 3526. https://doi.org/10.1111/cas.14602

Trifluoroacetic acid (TFA) is a common counterion from the purification process using High-Performance Liquid Chromatography (HPLC). The presence of TFA can affect the peptide's net weight, appearance, and solubility.

Impact on Net Weight: The TFA salt contributes to the total mass of the product. In most cases, the peptide content constitutes >80% of the total weight, with TFA accounting for the remainder.

Solubility: TFA salts generally enhance the solubility of peptides in aqueous solutions.

In Biological Assays: For most standard in vitro assays, the residual TFA levels do not cause interference. However, for highly sensitive cellular or biochemical studies, please be aware of its presence.